CD BioGlyco Releases One-Stop Services for Glycoprotein-Based Vaccine Development

Today, CD BioGlyco, a leading provider of glycobiology research and development services, announced the release of its new one-stop services for glycoprotein-based vaccine development, providing highly specialized platforms and various systematic and innovative solutions for the design, expression or synthesis of glycoprotein vaccine candidates.

Glycoprotein-based vaccines are a new generation of vaccines that are designed to mimic the natural structure of viral and bacterial pathogens. This can elicit a stronger and more specific immune response than traditional vaccines. Glycoprotein-based vaccines also have the potential to be more effective against a wider range of pathogens.

CD BioGlyco's one-stop services for glycoprotein-based vaccine development are designed to help researchers and biotechnology companies accelerate the development and commercialization of their glycoprotein-based vaccines. The services include:

12. Establish glyco-engineered yeast systems, plant systems, insect cell systems, mammalian cell systems, and viral vector systems to express immunogenic glycoproteins.
13. Chemical and chemoenzymatic platforms to perform site-specific glycosylation, and to ensure that the highly purified homogeneous glycoprotein vaccine candidates obtained are efficiently and simply operated under mild conditions.
14. Customized glycoprotein remodeling services, which can use natural chemical linkage (NCL), expressed protein ligation (EPL), and chemoenzymatic methods to obtain glycoproteins of interest.

Service advantages

• The product has strong immunogenicity and stable quality
• Multiple stable expression systems
• Fast speed, short experiment period
• Comprehensive vaccine process quality assessment system
• Customizable experimental programs based on different research needs
• One-stop service covering design, production, and inspection

“We are excited to release our new one-stop services for glycoprotein-based vaccine development," said Anna, one of the representative speakers from CD BioGlyco. "We are committed to helping our clients develop safe and effective glycoprotein-based vaccines that can protect people from a wide range of infectious diseases."

Additionally, Glycopeptide-based Cancer Vaccine Development, Carbohydrate-based Vaccine Development, and Carbohydrate-based Vaccine Adjuvant Development are also available at CD BioGlyco.

To know more detailed information about the one-stop custom services for glycoprotein-based vaccine development released by CD BioGlyco, please visit https://www.bioglyco.com/glycoprotein-based-vaccine-development.html.